You are here: Industry Insights > blood cancer

News List

Telix Pharmaceuticals acquires Swiss-German biotechnology company TheraPharm pharmaceutical-business-review
December 01, 2020
Telix Pharmaceuticals announces it has entered into an agreement with Scintec Diagnostics to acquire TheraPharm GmbH, a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of hematology.
AbbVie’s Venclyxto gets NICE blood cancer backing pharmatimes
November 12, 2020
AbbVie’s Venclyxto (venetoclax) has been recommended for use by the National Institute of Health and Care Excellence (NICE) as a routine treatment for chronic lymphocytic leukaemia (CLL).
Sanofi’s blood cancer drug Sarclisa meets primary endpoint in IKEMA trial pharmaceutical-business-review
May 15, 2020
Sanofi said that its blood cancer drug Sarclisa (isatuximab) has achieved the primary goal of a phase 3 trial in patients with relapsed multiple myeloma.
DARZALEX Shows Overall Survival Benefit in Multiple Myeloma Patients americanpharmaceuticalreview
December 16, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 ALCYONE study, which showed the addition of DARZALEX® ...
Bristol-Myers Squibb’s Liso-Cel meets key endpoints in blood cancer trial pharmaceutical-business-review
December 11, 2019
Bristol-Myers Squibb announced that its blood cancer treatment lisocabtagene maraleucel (liso-cel) has achieved its primary and secondary endpoints in TRANSCEND NHL 001 study.
Notable Labs brings on 2 development executives ahead of its first blood cancer trials fiercebiotech
February 27, 2019
After launching its first in-house R&D program last month, cancer drug-testing startup Notable Labs has brought on two biopharma executives to take charge of its clinical operations and drug development work....
ASH18: J&J shells out $500M to sew up Argenyx's blood cancer hopeful cusatuzumab fiercebiotech
January 03, 2019
As the biggest and brightest in the blood cancer world came together for the ASH conference this weekend, European biotech Argenx was busy making a big biobucks deal......
Astellas scores first US blood cancer approval with Xospata pharmaphorum
December 03, 2018
The FDA has approved Astellas’ Xospata for certain patients with acute myeloid leukaemia – the company’s first drug approved in blood cancer.
Janssen’s first-of-its-kind report combats blood cancer myths in APAC biospectrumasia
September 17, 2018
The report was developed by the Janssen Pharmaceutical Companies of Johnson & Johnson and supported by The Max Foundation.
NICE OKs three new therapies for blood cancer pharmatimes
July 09, 2018
Cost regulators for the NHS are recommending that three new types of treatment for people with blood cancer are made available on the NHS England and Wales.

Previous page 1 2 3 Next page